Quantification of insulin-like growth factor I (IGF-I) without interference by IGF binding proteins

D D De León1, Y Asmerom

  • 1Department of Physiology, Loma Linda University School of Medicine, CA 92350, USA.

Endocrinology
|May 1, 1997
PubMed

Insights

A new chemiluminescent dot blot assay offers rapid Insulin-like Growth Factor-I (IGF-I) determination in cell culture media. This method avoids interference from IGF binding proteins (IGFBPs), unlike traditional radioimmunoassays.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Assay Development

Background:

  • Insulin-like Growth Factor-I (IGF-I) is crucial for cell growth and differentiation.
  • Accurate measurement of IGF-I in cell culture is essential for research.
  • Existing methods like radioimmunoassays (RIAs) can be affected by IGF binding proteins (IGFBPs).

Purpose of the Study:

  • To develop a rapid and reliable assay for quantifying IGF-I in serum-free conditioned media (CM).
  • To evaluate the interference of IGFBPs in the developed assay compared to RIAs.

Main Methods:

  • Development of a chemiluminescent dot blot assay for IGF-I detection.
  • Testing the interference of all six IGFBPs on the dot blot assay.
  • Comparison of IGF-I detection with a standard RIA using the same monoclonal antibody.
  • Quantification of chemiluminescence using phosphorimager and Molecular Analyst software.

Main Results:

  • The chemiluminescent dot blot assay successfully detected IGF-I in CM without interference from IGFBPs.
  • All six IGFBPs bound to 125I IGF-I but did not interfere with detection on dot blots.
  • A comparable RIA showed interference from IGFBP-1, IGFBP-2, and IGFBP-4.
  • The dot blot assay demonstrated sensitivity (0.125-8.0 ng/mL), specificity (<1% cross-reactivity with IGF-II), and reproducibility (intra-assay variance ≤6%, inter-assay variance <12%).

Conclusions:

  • The developed chemiluminescent dot blot assay provides a robust, sensitive, and specific method for IGF-I quantification in serum-free CM.
  • This assay overcomes the limitations of RIAs by eliminating IGFBP interference.
  • The assay is not suitable for serum or serum-containing media due to reagent sensitivity to serum components.